STAAR Surgical (NASDAQ: STAA) reported Q4 EPS of $0.02, $0.02 better than the analyst estimate of $0.00. Revenue for the quarter came in at $31.2 million versus the consensus estimate of $30.27 million.

Fourth Quarter 2018 Overview

• Net Sales of $31.2 Million Up 26% from the Prior Year Quarter
• ICL Sales Up 41% and Units Up 54% from the Prior Year Quarter
• Gross Margin at 73.7% of Sales from 69.9% of Sales in the Prior Year Quarter
• Fourth Quarter Net Income of $0.02 per Share vs. Prior Year Net Loss of ($0.00) Per Share
• Cash, Cash Equivalents and Restricted Cash Ended the Quarter at $104.0 Million

“2018 was a breakout year for STAAR. The transformation of the business over the past two years has created a strong trajectory toward paradigm change in refractive vision correction delivering visual freedom. Lens based correction of Myopia is becoming a preferred surgical solution and EVO ICL only clinics are opening in Asia and Europe. We expect our momentum to continue with strong clinical evidence from refractive surgeons publishing ever more data supporting the safety and effectiveness of the ICL,” said Caren Mason, President and CEO. “Surgeons refer to the ICL patient as their ‘happiest patients’ and 99.4% of patients in a Patient Registry said they would have the procedure again. As such, we far exceeded our projection of breaking the $100.0 million revenue mark in 2018 by achieving $124.0 million in revenue. In fact, our ICL sales alone recorded $101.1 million in sales. My appreciation to the entire STAAR team and our surgeon partners around the globe for such outstanding performance.”

For earnings history and earnings-related data on STAAR Surgical (STAA) click here.